GlassScriptPhysician profile
Michael R Koteles
NPI 1093799959
$10,257.22
in general payments reported to CMS, 2019-2025
44 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $1,533 · 2021: $1,802 · 2022: $1,890 · 2023: $2,058 · 2024: $1,039 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887 · Consulting Fee: $235 · Gift: $109 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.46 |
| Consulting Fee | $235.00 |
| Gift | $109.40 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,139.04 | 2019-2025 | Prolia, Repatha, Prolia |
| Lilly USA, LLC | $1,028.30 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $886.58 | 2021-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Novo Nordisk INC | $777.16 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.36 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $706.88 | 2019-2023 | Farxiga |
| Mannkind Corporation | $492.98 | 2019-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $449.68 | 2019-2023 | |
| Radius Health, INC. | $347.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $346.70 | 2019-2021 | |
| Corcept Therapeutics | $275.38 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $261.11 | 2020-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $212.56 | 2020-2021 | |
| Abbvie INC. | $211.34 | 2019-2022 | |
| Medtronic, INC. | $209.07 | 2021-2023 | Eea, Minimed 770g, Inpen Smart Insulin Delivery System |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Koteles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.